Aleksandar Murgaski

Aleksandar Murgaski

Auto-generated profile, based on publicly available information

Aleksandar Murgaski

King’s College London 3 Centre for Inflammation Biology and Cancer Immunology, Cancer Research UK City of London Centre, School of Immunology and Microbial Sciences London, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
AMAleksandar Murgaski
Aleksandar Murgaski
MKMáté Kiss
Máté Kiss
HDHelena Van Damme
Helena Van Damme
DKDaliya Kancheva
Daliya Kancheva
IVIsaure Vanmeerbeek
Isaure Vanmeerbeek
DLDamya Laoui
Damya Laoui
Agonistic αCD40 therapy has been shown to inhibit cancer progression in only a fraction of patients. Understanding the cancer cell–intrinsic and microenvironmental determinants of αCD40 therapy response is therefore crucial to identify responsive patient populations and to design efficient combinatorial treatments. Here, we show that the therapeutic efficacy of αCD40 in subcutaneous melanoma relies on preexisting, type 1 classical dendritic cell (cDC1)–primed CD8+ T cells. However, after administration of αCD40, cDC1s were dispensable for antitumor efficacy. Instead, the abundance of activated cDCs, potentially derived from cDC2 cells, increased and further activated antitumor CD8+ T cells. Hence, distinct cDC subsets contributed to the induction of αCD40 responses. In contrast, lung carcinomas, characterized by a high abundance of macrophages, were resistant to αCD40 therapy. Combining αCD40 therapy with macrophage depletion led to tumor growth inhibition only in the presence of strong neoantigens. Accordingly, treatment with immunogenic cell death–inducing chemotherapy sensitized lung tumors to αCD40 therapy in subcutaneous and orthotopic settings. These insights into the microenvironmental regulators of response to αCD40 suggest that different tumor types would benefit from different combinations of therapies to optimize the clinical application of CD40 agonists. Significance: This work highlights the temporal roles of different dendritic cell subsets in promoting CD8+ T-cell–driven responses to CD40 agonist therapy in cancer.

16 September 2025 in Cancer Research
Verified
Journal Article
Open access
SASana M. Arnouk
Sana M. Arnouk
DKDaliya Kancheva
Daliya Kancheva
HDHelena Van Damme
Helena Van Damme
Guillaume E CourtoyGuillaume E Courtoy
Guillaume E Courtoy
RBRomina Mora Barthelmess
Romina Mora Barthelmess
JGJo A. Van Ginderachter
Jo A. Van Ginderachter
Eliminating immunosuppressive cells, such as regulatory T cells (Treg), is a promising approach to boost immunotherapy success. However, this approach may suffer from systemic autoimmune adverse events, highlighting the need to specifically target tumor-infiltrating Tregs (tiTreg). Based on cellular indexing of transcriptomes and epitopes by sequencing and single-cell RNA sequencing data from mouse models of triple-negative breast cancer (TNBC) and colorectal carcinoma, as well as a meta-analysis of human TNBC and colorectal carcinoma datasets, we obtained a comprehensive overview of the tiTreg heterogeneity and IL1R2 expression. Several IL1R2-expressing tiTreg clusters were identified in mouse and human TNBC and colorectal carcinoma tumors, with some level of conservation. IL1R2 was identified as a surface marker that was most highly expressed by activated and strongly T-cell–suppressive tiTregs in the tumor microenvironment but not by peripheral Tregs. IL1R2 upregulation resulted from T-cell receptor–mediated Treg triggering in a Rel-dependent fashion, but the receptor itself was dispensable for tiTreg abundance and activation and did not influence tumor growth. Accordingly, the blockade of IL1R2, by using an Ab-dependent cell-mediated cytotoxicity (ADCC)–dead anti-IL1R2 nanobody-Fc construct, had no impact on tumor growth. Conversely, anti-IL1R2 nanobody-Fc constructs with an optimized ADCC functionality, mediated by the SDALIE mutation, resulted in the specific depletion of IL1R2+ tiTregs, elicited antitumor immunity, and reduced tumor growth in synergy with anti–PD-1 therapy. Collectively, these findings identify IL1R2 as a marker for highly activated and suppressive tiTregs that is suitable as a target for ADCC-dependent tiTreg depletion, which can synergize with immune checkpoint blockade. Significance: IL1R2+ Treg depletion using IL1R2-targeting ADCC-prone constructs is a potential cancer therapy to selectively target tumor-infiltrating Tregs and circumvent autoimmune complications caused by systemic Treg depletion.

31 March 2023
Verified
Other
Open access
AMAleksandar Murgaski
Aleksandar Murgaski
MKMáté Kiss
Máté Kiss
HDHelena Van Damme
Helena Van Damme
DKDaliya Kancheva
Daliya Kancheva
IVIsaure Vanmeerbeek
Isaure Vanmeerbeek
DLDamya Laoui
Damya Laoui
Supplementary Figure from Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages

26 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAleksandar Murgaski
Aleksandar Murgaski
MKMáté Kiss
Máté Kiss
HDHelena Van Damme
Helena Van Damme
DKDaliya Kancheva
Daliya Kancheva
IVIsaure Vanmeerbeek
Isaure Vanmeerbeek
DLDamya Laoui
Damya Laoui
Agonistic αCD40 therapy has shown to inhibit cancer progression, but only in a fraction of patients. Hence, understanding the cancer cell-intrinsic and microenvironmental determinants of αCD40 therapy response is crucial to identify responsive patient populations and design efficient combination treatments. Here, we showed that the therapeutic efficacy of αCD40 in responder melanoma tumours, relied on pre-existing cDC1-primed CD8 + T cells, however cDC1s were dispensable after αCD40 administration. Surprisingly, in response to αCD40 the abundance of activated cDCs, potentially derived from cDC2s increased, thereby further activating antitumour CD8 + T cells. Hence, distinct cDC subsets are required to induce αCD40 responses. By contrast, lung tumours, characterised by a high abundance of macrophages, were resistant to αCD40 therapy. Combining αCD40 therapy with macrophage depletion led to tumour growth inhibition only in the presence of strong neoantigens. Accordingly, treatment with immunogenic cell-death inducing chemotherapy sensitised non-immunogenic tumours to αCD40 therapy.

31 March 2023
Verified
Other
Open access
AMAleksandar Murgaski
Aleksandar Murgaski
MKMáté Kiss
Máté Kiss
HDHelena Van Damme
Helena Van Damme
DKDaliya Kancheva
Daliya Kancheva
IVIsaure Vanmeerbeek
Isaure Vanmeerbeek
DLDamya Laoui
Damya Laoui
Supplementary Figure from Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages

31 March 2023
Verified
Other
Open access
AMAleksandar Murgaski
Aleksandar Murgaski
MKMáté Kiss
Máté Kiss
HDHelena Van Damme
Helena Van Damme
DKDaliya Kancheva
Daliya Kancheva
IVIsaure Vanmeerbeek
Isaure Vanmeerbeek
DLDamya Laoui
Damya Laoui
Supplementary Data from Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages